Lung cancer trials in China

In China 1143 Also abroad 2747

1,143 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
Where
Beijing, Bengbu, Changchun, Dalian, Dongguan, Fuzhou, Guangzhou, Haerbin, Hangzhou, Jinan, Kunming, Nanchang, Shanghai, Shenyang, Taiyuan, Tianjin, Ürümqi, Xiamen, Zhengzhou, Zhuhai
Age
18 years and over
People
170
Run by
3D Medicines (Sichuan) Co., Ltd.
See details and how to joinNCT05024214
Phase 3Taking people
Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
Where
Tianjin
Age
18 years and over
People
390
Run by
3D Medicines (Sichuan) Co., Ltd.
See details and how to joinNCT06123754
Phase 2Taking people
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
Where
Beijing, Guangzhou, Zhejiang
Age
18 years and over
People
30
Run by
Jianxing He
See details and how to joinNCT07492342
Phase 1/2Not yet taking people in China
Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
Where
Beijing, Taiyuan
Age
18 years and over
People
53
Run by
Shanxi Province Cancer Hospital
See details and how to joinNCT07486648
No phaseTaking people
Diagnostic Value and Safety of Combined Biopsy for Mediastinal Metastasis of Lung Cancer
Where
Chongqing
Age
18 years and over
People
240
Run by
Third Military Medical University
See details and how to joinNCT07488507
Phase 2Taking people
Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
Where
Guangzhou
Age
18 years and over
People
40
Run by
Avistone Biotechnology Co., Ltd.
See details and how to joinNCT07336732
Phase 4Not yet taking people in China
A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
Where
Qingdao, Weihai, Yantai, Zibo
Age
18 years and over
People
20
Run by
The Affiliated Hospital of Qingdao University
See details and how to joinNCT07485920
No phaseTaking people
Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）
Where
Hangzhou, Wuhan
Age
18 years and over
People
500
Run by
Qian Chu
See details and how to joinNCT07388771
Phase 2Not yet taking people in China
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Where
Changsha
Age
18 years to 80 years
People
30
Run by
Hunan Province Tumor Hospital
See details and how to joinNCT07001995
Phase 4Not yet taking people in China
A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens
Where
Shanghai
Age
18 years and over
People
122
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT07469488
No phaseNot yet taking people in China
Video Double-Lumen Tube for Secondary Pulmonary Resection
Where
Hangzhou, Yiwu
Age
18 years and over
People
500
Run by
Zhejiang University
See details and how to joinNCT07467005
Phase 1/2Taking people
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
Where
Shenzhen
Age
18 years to 75 years
People
48
Run by
Beijing Biotech
See details and how to joinNCT07467863
Phase 2Taking people
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
Where
Shanghai
Age
18 years to 75 years
People
124
Run by
Shanghai Chest Hospital
See details and how to joinNCT05798845
Phase 2Taking people
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
Where
Shanghai
Age
18 years and over
People
53
Run by
Fudan University
See details and how to joinNCT06775743
Phase 2Taking people
IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
Where
Beijing, Foshan, Guangzhou, Nanchang, Nanning, Shijiazhuang
Age
18 years to 75 years
People
48
Run by
Guangdong Association of Clinical Trials
See details and how to joinNCT07198841
No phaseTaking people
A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging
Where
Chengdu, Guangzhou, Hangzhou, Shenyang, Wuhan, Yangzhou
Age
18 years and over
People
5,500
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07463300
No phaseTaking people
Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients
Where
Guangzhou
Age
18 years to 75 years
People
82
Run by
Guangzhou University of Traditional Chinese Medicine
See details and how to joinNCT05378334
Phase 2Taking people
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Where
Changsha, Chongqing, Guiyang, Hong Kong, Macao, Nanchang, Nanning, Shenyang, Taiyuan, Wuhan, Xinxiang, Zhuzhou
Age
18 years to 75 years
People
70
Run by
Second Xiangya Hospital of Central South University
See details and how to joinNCT06951646
Phase 2Taking people
Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
Where
Beijing
Age
18 years and over
People
108
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07120282
Phase 2Taking people
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Where
Beijing
Age
18 years to 75 years
People
210
Run by
Guangzhou JOYO Pharma Co., Ltd
See details and how to joinNCT06895031
Phase 3Taking people
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Where
Anyang, Beijin, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Gannan, Guangzhou, Guiyang, Harbin, Hengyang, Jiangmen, Jinan, Jingzhou, Lanzhou, Linyi, Liuzhou, Longyan, Mianyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shaxi, Shenyang, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Wuhan, Xi’an, Xinxiang, Xuzhou, Yinchuan, Zaozhuang, Zhangzhou, Zhengzhou, Zunyi
Age
18 years and over
People
560
Run by
Akeso
See details and how to joinNCT07010263
Phase 2Taking people
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
Where
Wuhan
Age
18 years to 75 years
People
80
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07264816
No phaseTaking people
An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC
Where
Beijing
Age
18 years and over
People
30
Run by
Peking Union Medical College Hospital
See details and how to joinNCT07452003
Phase 1Taking people
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
Where
Changsha, Hangzhou, Shanghai
Age
18 years to 75 years
People
162
Run by
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
See details and how to joinNCT06424665
Phase 2Taking people
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Where
Guangzhou
Age
18 years to 75 years
People
47
Run by
Sun Yat-sen University
See details and how to joinNCT06719700